C4 Therapeutics Announces Pricing of Public Offering
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a…
Pharmaceuticals, Biotechnology and Life Sciences
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a…
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming…
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized…
Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17SUNNYVALE, Calif. and NEW YORK, June 16, 2021 (GLOBE…
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO…
Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and…
GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to…
Dr. Slavin Brings Deep Clinical, Academic and Industry Experience to New RoleSALT LAKE CITY, June 16, 2021 (GLOBE NEWSWIRE) —…
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in…
– All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic…